ANEW MEDICAL, INC. Appoints New CFO
NEW YORK — ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a biotechnology company based in the U.S. that focuses on developing cell and gene therapies for aging and age-related conditions, has announced the appointment of Jeffrey LeBlanc as its new Chief Financial Officer (CFO). He takes over from interim CFO Edward Cong Wang, who previously served as the CFO of Redwoods Acquisition Corp, the organization through which ANEW merged.
“We are excited to welcome Jeff LeBlanc to our team,” said Dr. Joseph Sinkule, the Founder, Chairman, and CEO of ANEW. “Jeff comes with more than twenty years of extensive experience in financial management, launching new initiatives, and successfully guiding business exits. Earlier in his career, he held key investment positions at Greenlight Capital and GE Capital, and he began his professional path at McKinsey and Co. He graduated from MIT with a Bachelor of Science in Chemical Engineering and also holds an MBA from Harvard Business School.”
Overview of ANEW MEDICAL, INC.
About the Company
ANEW MEDICAL, INC. (NASDAQ: WENA) is an innovative biopharmaceutical company dedicated to developing patented technologies that aim to modify diseases affecting the brain and central nervous system (CNS). These technologies are vital for treating neurodegenerative and age-related conditions. The company has secured exclusive global rights to groundbreaking technologies and expertise for creating advanced protein, gene, and cell therapies that target age-related diseases, including Alzheimer’s, Parkinson’s Disease, ALS, multiple sclerosis, and various rare neurodegenerative disorders. Currently, ANEW's portfolio features its proprietary gene therapy platform that utilizes DNA and RNA for therapeutic and diagnostic purposes. Additionally, the company is engaged in clinical-stage programs that include antibody biologics targeting cancer and autoimmune diseases, as well as a needle-free dry powder jet autoinjector called Nanoject for drug delivery.
Management Expertise
ANEW is led by a talented team of professionals and advisors who possess extensive experience in biopharmaceutical product development and commercialization. This strategic leadership equips the company to effectively navigate the complexities of the biotechnology industry.
Contact Information
For more information, please reach out to:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com
Frequently Asked Questions
1. Who is the new Chief Financial Officer of ANEW MEDICAL, INC.?
The new Chief Financial Officer of ANEW MEDICAL, INC. is Jeffrey LeBlanc.
2. What experience does Jeffrey LeBlanc bring to ANEW MEDICAL, INC.?
Jeffrey LeBlanc brings over 20 years of experience in managing financial operations, launching new ventures, and achieving successful business exits, with investment roles at Greenlight Capital and GE Capital.
3. What areas does ANEW MEDICAL, INC. focus on in biotechnology?
ANEW MEDICAL, INC. focuses on developing cell and gene-based therapies for aging and age-related diseases, specifically targeting conditions like Alzheimer’s and Parkinson’s disease.
4. What unique technologies does ANEW MEDICAL, INC. develop?
The company develops patented disease-modifying technologies for the brain and central nervous system, along with gene therapy programs using DNA and RNA.
5. How can investors contact ANEW MEDICAL, INC.?
Investors can contact Eric Boyd in Investor Relations via email at IR@anewmeds.com.
